Prasugrel

A reduced dose of prasugrel in patients with ACS maintained its anti-ischemic effect without elevated bleeding risk compared with patients treated with a standard dose of ticagrelor, regardless of age or weight, researchers found.

Assessment of safety and efficacy of ticagrelor (Brilinta, AstraZeneca) vs. prasugrel (Effient, Daiichi Sankyo/Eli Lilly) in patients with ACS for whom invasive evaluation was planned.

PARIS — In this video exclusive, Dipti Itchhaporia, MD, FACC, with Hoag Heart and Vascular Institute in Newport Beach and University of California, Irvine, and vice president-elect of the American College of Cardiology, provides highlights from the 2019 European Society of Cardiology Congress.

PARIS — A strategy guided by CYP2C19 genotyping conferred reduced bleeding risk and similar thrombotic risk compared with standard treatment in patients needing oral P2Y12 inhibitor therapy after PCI with stenting for STEMI, according to findings from the POPular Genetics trial presented at the European Society of Cardiology Congress.

PARIS — In patients with acute coronary syndromes, with or without ST-segment elevation, the rate of death, MI or stroke was significantly reduced at 1 year with prasugrel compared with ticagrelor, without an increase in major bleeding, according to a head-to-head comparison of both strategies.

PARIS — New data from the POPular AGE study support the use of clopidogrel over ticagrelor and prasugrel, based on significant reduction in bleeding, in patients aged 70 years and older with non-ST-elevation ACS.

In recent years, data have emerged showing a variety of medical therapies can improve outcomes of patients with peripheral artery disease.